United Therapeutics Corporation and SteadyMed announced on Friday, July 20, the termination of the waiting period under the Hart-Scott-Rodino (HSR) Act relating to United Therapeutics’ previously announced acquisition of SteadyMed.
United Therapeutics and SteadyMed entered into a definitive merger agreement under which United Therapeutics will acquire SteadyMed for US$4.46 per share in cash at closing and one contractual contingent value right per share (subject to the Contingent Value Rights Agreement), which will represent the right to receive US$2.63 in cash upon the achievement of a milestone related to the commercialization of pharmaceutical.
The termination of the waiting period under the HSR Act satisfies one of the conditions to closing of the acquisition, which remains subject to other closing conditions, including the approval of the acquisition by SteadyMed’s shareholders. A meeting of SteadyMed’s shareholders to vote upon the acquisition will be held on July 30, 2018.
The Board of Directors of SteadyMed has unanimously recommended that SteadyMed’s shareholders vote to approve the acquisition.
Full Content: Nasdaq
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Australia’s Major Supermarkets Face Scrutiny Over Profit Margins Amid Rising Prices
Mar 21, 2025 by
CPI
Fired FTC Commissioners Warn of Potential White House Influence Over Mergers
Mar 20, 2025 by
CPI
Dr. Matthew Backus Joins Compass Lexecon as an Affiliate
Mar 20, 2025 by
CPI
UK to Boost Broadband Competition While Capping Openreach Charges, Says Ofcom
Mar 20, 2025 by
CPI
Singapore Competition Watchdog Yet to Receive Formal Notification on Grab-GoTo Merger
Mar 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li